Clinical implications of prostate-specific antigen (PSA)

Current Opinion in Urology

Volumn 8, Issue 5, 1998, Pages 401-406

  Oakley, Neil ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BIOPSY; BLOOD LEVEL; CASTRATION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; EXPERIMENTAL MODEL; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME;

EID: 0031785612     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199809000-00007     Document Type: Review

References (54)

1. Lilja H. Prostate specific antigen: molecular forms and the human kallikrein gene family. Br J Urol 1997; 79 (Suppl 1):44-48. A succinct but comprehensive overview of the rationale behind using the different molecular forms of PSA in serum.
2. Papsidero LD, Wang MC, Valenzuala LA, Murphy GP, Chu TM. A prostate antigen in sera of prostate cancer patients. Cancer Res 1980; 40:2428-2432.
3. Montie JE, Meyers SE. Defining the ideal tumour marker for prostate cancer. Urol Clin North Am 1997; 24:247-252.
4. Tchetgen M-BN, Oesterting JE. The effect of prostatitis, urinary retention, ejaculation and ambulation on the serum prostate specific antigen concentration. Urol Clin North Am 1997; 24:283-291. One PSA is often not enough as this review highlights potential influences.
5. Klein LT, Lowe FC. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am 1997; 24:293-297. This emphasizes that it is important to know how much alteration can be caused iatrogenically.
6. Bedlushi MC, Oesterling JE. Prostate-specific antigen density. Urol Clin North Am 1997; 24:323-332. A contemporary review of one of the emerging refinements of PSA.
7. Richardson TD, Oesterling JE. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am 1997; 24:339-351. A review of age/race-referenced PSA by its initial proponent.
8. Carter HB, Pearson JD. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Ural Clin North Am 1997; 24:333-338. The significant cut-off levels are discussed along with important criteria for performing and interpreting PSA velocity.
9. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. Urol Clin North Am 1997; 24:353-365. The theory behind free PSA, the clinical studies and their limitations.
10. Babaian RJ. Current status of enhancing the detection of prostate cancer. Prostate 1997; 31:204-205.
11. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997; 157:1315-1321.
12. Nixon RG, Brawer MK. Enhancing the specificity of prostate specific antigen: an overview of PSA density, velocity and age specific ranges. Br J Urol 1997; 79 (Suppl 1):61-67.
13. Dearnaley DP, Melia J. Early prostate cancer: to treat or not to treat? Lancet 1997; 349:892-893.
14. Scardino P. Problem of prostate cancer. J Urol 1994; 152:1677-1678.
15. Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connelly R, Moul JW, Sesterhenn IA. Prostate specific antigen detected prostate cancer (stage T1c): an analysis of whole mount prostatectomy specimens. Prostate 1997; 32:59-64. This paper concludes that if a tumour can be detected by PSA rise, it is not insignificant.
16. Bangma Ch, Rietbergen JBW, Schroder FH. Prostate specific antigen as a screening test. The Netherlands experience. Urol Clin North Am 1997; 24:307-314. One of the few prospective screening trials aiming to address the question of whether we are reducing the mortality from prostate cancer.
17. Bouffioux. Prostate cancer: to screen or not to screen? Eur Urol 1997; 31 (Suppl 1):2-4.
18. Benoit RM, Naslund MJ. The socioeconomic implications of prostate specific antigen screening. Urol Clin North Am 1997; 24:451-458. This helps to give an insight into the imponderables of screening.
19. Stenman U-H. Prostate specific antigen, clinical use and staging: an overview. Br J Urol 1997; 79 (Suppl 1):53-60.
20. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL. Prostate-specific antigen as a screening test for prostate cancer. The United States experience. Urol Clin North Am 1997; 24:299-306. A comprehensive overview of the pertinent studies on low-level PSA and cancer risk.
21. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petras JA, Andriole GL. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324:1156-1161.
22. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localised prostate cancer. JAMA 1997; 277:1445-1451. This paper contains essential nomograms constructed from a multi-institutional database and formerly validated. By utilizing the variables of PSA, Gleason score and DRE, an accurate prediction of stage can be given to the patient. Fully informed consent and fully standardized treatment are thus available.
23. Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Petterson K, Schroder FH. The free to total prostate-specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997; 57:2191-2196. The latest update from the 'European Randomised Study of Screening for Prostate Cancer' prospective screening trials aiming to answer the question of whether or not we are reducing the mortality from prostate cancer.
24. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
25. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening lor prostate cancer with prostate specific antigen. JAMA 1996; 276:1309-1315.
26. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452-1455. The latest update on Catalan's work in PSA screening. Should we be reassured if the PSA is less than 4 ng/ml? This would suggest not. This prospective study included almost 1000 patients, and cancer was detected in 22% - of which 19% were not organ-confined.
27. Reissigl A, Bartsch G. Prostate specific antigen as a screening test. The Austrian experience. Urol Clin North Am 1997; 24:315-321. A revealing work on the trade-off between specificity and sensitivity.
28. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate specific antigen testing intervals for the detection of prostate cancer JAMA 1997; 277:1456-1460. A paper with practical advice on when to repeat the PSA.
29. Harris CH, Dalkin BL, Martin E, Marx PC, Ahmann FR. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/ml or less. J Urol 1997; 157:1740-1743. Another paper with practical advice on when to repeat the PSA.
30. Keetch DW, Catalona WJ, Smith DS. Serial prostate biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151:1571-1574.
31. Ukimura O, Durrani O, Babaian JR. Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 1997; 50:66-72.
32. Perachino M, di Ciolo L, Barbetti V, Ardoino S, Vitali A, Introini C, Vigliercio G, Puppo P. Results of rebiopsy for suspected prostate carcinoma in symptomatic men with elevated PSA levels. Eur Urol 1997; 32:155-159.
33. Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative biopsies. J Urol 1997; 158:2162-2167. This helps to answer that most vexing of questions, who to put through the trauma of re-biopsy.
34. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate J Urol 1997; 158:505-509.
35. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate specific antigen levels in serum: an elevation of day to day physiological fluctuations in a well defined cohort of 24 patients. J Urol 1997; 157:2183-2190. Indicates the worrying wide biological variation in PSA.
36. Carter HB, Morrel CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, Chan DW, Fozard JL, Walsh PC. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostatic disease. Cancer Res 1992; 52:3323-3328.
37. Optenberg SA, Clark JY, Brawer MK, Thompson IM, Stein CR, Friedrichs P. Development of a decision-making tool to predict risk of prostate cancer: the cancer of the prostate risk index (CAPRI) test. Urology 1997; 50:665-671. Read this and try the computer-assisted decision tool software out.
38. Rees MA, Resnick MI, Oesterling JE. Use of prostate specific antigen, Gleason score and digital rectal examination in staging patients with newly diagnosed prostate cancer. Urol Clin North Am 1997; 24:379-388. Research extrapolated into sound clinical advice.
39. Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 1997; 24:389-394. Research extrapolated into sound clinical advice.
40. Thiel R, Pearson JD, Epstein JI, Walsh PC, Carter HB. Role of prostate specific antigen velocity in prediction of final pathologic stage in men with localised prostate cancer. Urology 1997; 49:716-720.
41. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Prognostic significance of prostate specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology 1997; 49:887-893. This is further work to stress that T1c tumours are not insignificant. This study confirms the predictive power of PSA but also lowers the safe limit regarding organ-confined disease down to 7.0 ng/ml.
42. O'Dowd, GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997; 158:687-698. A well-written review of an area of much work.
43. Schellhammer PF, El-Mahadi AM, Kuban DA, Wright GL Jr. Prostate-specific antigen after radiation therapy. Urol Clin North Am 1997; 24:407-414. A concise well-written collation of the relevant data.
44. Ingenito AC, Ennis RD Hsu IC, Begg M, Benson MC, Schiff PB. Reexamining the role of prostate-specific density in predicting outcome for clinically localised prostate cancer. Urology 1997; 50:73-78.
45. Critz FA, Levinson AK, Williams WH, Holladay DA, Holladay CT. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997; 49:322-326. A simple study with concise but clinically relevant conclusions. Speculates on whether, if you can predict failure by the PSA nadir, adjuvant therapy is appropriate.
46. Lee WR, Hanks GE, Hanlon A. Increasing prostate specific antigen profile following definitive radiation therapy for localised prostate cancer: clinical observations. J Clin Oncol 1997; 15:230-238.
47. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24:395-406. A summary of the current thinking on the significance of PSA profiles post-prostatectomy.
48. Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology 1997; 49:737-742.
49. Smith JA, Lange PH, Janknegt RA, Abbou CC, Degery A. Serum markers as predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 1997; 157:1329-1334. This is the answer to the question that the patient wants most.
50. Woodrum DI, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 158:5-12. An exhaustive summary as to the pitfalls of free PSA studies.
51. Presti JC, Hovey R, Bhargava V, Carrol IPR, Shinohara K. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations. J Urol 1997; 157:907-912.
52. Witherspoon LR, Lapeyrolerie T. Sensitive prostate specific antigen measurements identity men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol 1997; 157:1322-1328.
53. Israeli RS, Grob M, Fair WR. Prostate specific membrane antigen and other prostatic tumour markers on the horizon. Urol Clin North Am 1997; 24:439-450.
54. Olsson CA, de Vries GM, Buttyan RB, Katz AE. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol Clin North Am 1997; 24:367-378. An update on the technology and implications of RT-PCR for prostate cancer.